|本期目录/Table of Contents|

[1]任德标,周丽娟,林智刚,等.CT放射组学对NSCLC患者抗PD-L1疗效分析[J].中华肺部疾病杂志,2021,(05):614-616.[doi:10.3877/cma.j.issn.1674-6902.2021.05.017]
点击复制

CT放射组学对NSCLC患者抗PD-L1疗效分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年05期
页码:
614-616
栏目:
临床研究
出版日期:
2021-10-20

文章信息/Info

Title:
-
作者:
任德标; 周丽娟; 林智刚; 刘威宏
363000 漳州,中国人民解放军联勤保障部队第九〇九医院医学影像科
Author(s):
-
关键词:
非小细胞肺癌;  CT放射组学;  程序性死亡配体-1;  预测意义
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2021.05.017
摘要:
目的 分析CT放射组学对非小细胞肺癌(NSCLC)患者抗程序性死亡配体-1(PD-L1)疗效及预测意义。方法 选择2018年10月至2019年1月于我院就诊的63例NSCLC患者为对象,所有受试者均接受诊断性增强胸部 CT 扫描,并接受2周3 mg/kg 剂量或240 mg固定剂量的静脉注射纳武单抗治疗,随访4个治疗周期,于末次随访时评估抗PD-L1疗效。并根据患者抗PD-L1疗效,分为缓解组和进展组。采用Lasso-logistic回归方程筛选价值高的CT放射组学特征,通过绘制ROC曲线鉴别其对NSCLC患者治疗效果的预测价值。结果 随访2年,截止末次随访时间2021年1月26日,共1例患者失访,5例患者死亡,57例患者完成随访,共38例患者疾病进展为进展组,19例患者疾病缓解为缓解组。采用Lasso-logistic回归方程共提取462个CT放射组学特征,通过Lasso-logistic回归模型选取出系数非零特征,绘制ROC曲线显示预测患者抗PD-L1疗效的AUC为0.991(95%CI 0.938～987),灵敏度为94.23%,特异度为96.43%。结论 基于CT放射组学建立的预测模型对NSCLC患者抗PD-L1治疗疗效的较高,可作为预测及评估 NSCLC患者抗PD-L1疗效。
Abstract:
-

参考文献/References:

1 Herbst RS, Garon EB, Kim DW, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study[J]. J Clin Oncol, 2020, 38(14): 1580-1590.
2 Mocan T, Sparchez Z, Craciun R, et al. Programmed cell death protein-1(PD-1)/programmed death-ligand-1(PD-L1)axis in hepatocellular carcinoma: prognostic and therapeutic perspectives[J]. Clin Transl Oncol, 2019, 21(6): 702-712.
3 Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies[J]. Lung Cancer, 2019, 135(1): 188-195.
4 Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death(PD)-1 and anti-programmed death-ligand 1(PD-L1)blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.
5 Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]. Oncologist, 2019, 24(1): 31+41.
6 Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer[J]. Cancer Immunol Res, 2020, 8(1): 108-119.
7 Polverari G, Ceci F, Bertaglia V, et al.(18)F-FDG pet parameters and radiomics features analysis in advanced nsclc treated with immunotherapy as predictors of therapy response and survival[J]. Cancers(Basel), 2020, 12(5): 1163.
8 Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer(NSCLC): recommendations of the European Expert Group[J]. Thorax, 2016, 71(2): 177-184.
9 冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[S]. 2009.
10 Akhurst T. Staging of non-small-cell lung cancer[J]. PET Clin, 2018, 13(1): 1-10.
11 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
12 陈 燏,王玉秀,闵凌峰. NIX蛋白表达与非小细胞肺癌临床病理特征及预后[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 412-416.
13 梁任隆, 彭小东, 余倩如, 等. 联合抗PD-1/PD-L1组合策略在肺癌治疗中的研究进展[J]. 中国老年学杂志, 2020, 40(21): 4687-4691.
14 Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes[J]. Clin Cancer Res, 2019, 25(15): 4592-4602.
15 Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer(NSCLC): what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75(1): 39-51.
16 Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9): 1441-1448.
17 Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer[J]. J BUON, 2019, 24(3): 883-888.
18 Hepp T, Othman A, Liebgott A, et al. Effects of simulated dose variation on contrast-enhanced CT-based radiomic analysis for non-small cell lung cancer[J]. Eur J Radiol, 2020, 124(1): 108804.
19 Hughes DJ, Chand G, Goh V, et al. Inter- and intraobserver agreement of the quantitative assessment of [(99m)Tc]-labelled anti-programmed death-ligand 1(PD-L1)SPECT/CT in non-small cell lung cancer[J]. EJNMMI Res, 2020, 10(1): 145.
20 Xing Y, Chand G, Liu C, et al. Early phase I study of a(99m)Tc-labeled anti-programmed death ligand-1(PD-L1)single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer[J]. J Nucl Med, 2019, 60(9): 1213-1220.

备注/Memo

备注/Memo:
通信作者: 刘威宏, Email: 470494639@qq.com
更新日期/Last Update: 2021-10-20